The type 2 diabetes market size is forecast to grow by USD 39.37 billionbetween 2022 and 2027 at a CAGR of 10.94%. The growth of the market is driven by the increasing prevalence of diabetes across the world. Type 2 diabetes is the most common type of diabetes. The number of patients with type-2 diabetes is increasing significantly due to being overweight and the lack of physical activities. The growing prevalence of the disease has created the need for advanced medications and the use of drugs, such as insulin. All these factors are driving the growth of the global type 2 diabetes market. For more insights on the historic (2017 to 2021) and forecast market size (2023 to 2027) – Request a report sample
Regional Analysis
By region, the global Type 2 diabetes market is segmented into North America, Europe, Asia, and the Rest of World (ROW). North America will account for 38% of market growth during the forecast period. The growth of the regional market can be attributed to factors such as the availability of advanced therapeutics and delivery techniques for type 2 diabetes and significant investments in R&D by vendors to develop new drugs.
Company Profiles
The type 2 diabetes market report includes information on the key products and recent developments of leading vendors, including:
- Amgen Inc. – The company offers type 2 diabetes drug named Biovitrum which has small molecule 11aHSD1 enzyme inhibitors for the treatment of metabolic diseases and certain other medical disorders.
- AstraZeneca Plc – The company offers Onglyza or saxagliptin drug which is used for adults with type 2 diabetes mellitus to improve glycaemic control in combination with diet and exercise.
- Boehringer Ingelheim International GmbH – The company offers Jardiance empagliflozin type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of cardiovascular death in patients with established cardiovascular disease.
- Cadila Pharmaceuticals Ltd. – The company offers type 2 diabetes products such as API and Zeta drugs.
Market Segmentation
- By drug-class, the market is segmented into insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, and others.
- By geography, the market is segmented into North America, Europe, Asia, and the Rest of World (ROW).
Get insights on the market contribution of various segments including country and region wise, historic (2017 to 2021), and forecast market size (2023 to 2027) –Request a Sample
Market Dynamics
The market is driven by factors such as the rising prevalence of diabetes, the rise in prevalence of obesity and changing lifestyles, and recent product approvals. However, the low diagnosis rate will hinder the market growth.
What`s New for 2023?
- Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession
- Global competitiveness and key competitor positions – Buy the Report!
Related Reports:
- The insulin market is estimated to grow at a CAGR of 1.77% between 2022 and 2027. The size of the market is forecast to increase by USD 1,662.41 million. The growing prevalence of diabetes is notably driving the market growth, although factors such as stringent regulations may impede the market growth.
- The ophthalmology therapeutics market is estimated to grow at a CAGR of 6.25% between 2022 and 2027. The size of the market is forecast to increase by USD 15.72 billion. The increase in the prevalence of eye diseases is notably driving the market growth, although factors such as the high costs of treatment may impede the market growth.
Technavio’s library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our “Basic Plan” at just USD 5,000 and get lifetime access to Technavio Insights
What are the key data covered in this type 2 diabetes market report?
- CAGR of the market during the forecast period.
- Detailed information on factors that will drive the growth of the market between 2023 and 2027
- Precise estimation of the size of the type 2 diabetes market and its contribution to the parent market.
- Accurate predictions about upcoming trends and changes in consumer behavior.
- Growth of the market across North America, Europe, Asia, and the Rest of World (ROW).
- A thorough analysis of the market’s competitive landscape and detailed information about vendors.
- Comprehensive analysis of factors that will challenge the growth of type 2 diabetes market vendors.
| Type 2 Diabetes Market Scope | |
| Report Coverage | Details |
| Base year | 2022 |
| Historic period | 2017-2021 |
| Forecast period | 2023-2027 |
| Growth momentum & CAGR | Accelerate at a CAGR of 10.94% |
| Market growth 2023-2027 | USD 39.37 billion |
| Market structure | Fragmented |
| YoY growth 2022-2023 (%) | 9.49 |
| Regional analysis | North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution | North America at 38% |
| Key countries | US, Germany, UK, China, India, Canada, Mexico, Italy,Spain, Japan, Australia, and South Korea |
| Competitive landscape | Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
| Key companies profiled | Amgen Inc., AstraZeneca Plc, Baxter International Inc., Biocon Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Daiichi Sankyo Co. Ltd., DM Pharma Marketing Pvt. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Merck KGaA, Novartis AG, Novo Nordisk AS, Pfizer Inc., Practo Technologies Pvt. Ltd., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Tonghua Dongbao Pharmaceutical Co. Ltd. |
| Market dynamics | Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
| Customization purview | If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse through Technavio’s Health Care Market Reports
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global type 2 diabetes market 2017 – 2021
- Exhibit 18: Historic Market Size – Data Table on Global type 2 diabetes market 2017 – 2021 ($ billion)
- 4.2 Drug class Segment Analysis 2017 – 2021
- Exhibit 19: Historic Market Size – Drug class Segment 2017 – 2021 ($ billion)
- 4.3 Distribution channel Segment Analysis 2017 – 2021
- Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ billion)
- 4.4 Geography Segment Analysis 2017 – 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ billion)
- 4.5 Country Segment Analysis 2017 – 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ billion)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
6 Market Segmentation by Drug Class
- 6.1 Market segments
- Exhibit 30: Chart on Drug Class – Market share 2022-2027 (%)
- Exhibit 31: Data Table on Drug Class – Market share 2022-2027 (%)
- 6.2 Comparison by Drug Class
- Exhibit 32: Chart on Comparison by Drug Class
- Exhibit 33: Data Table on Comparison by Drug Class
- 6.3 Insulin – Market size and forecast 2022-2027
- Exhibit 34: Chart on Insulin – Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Insulin – Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Insulin – Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Insulin – Year-over-year growth 2022-2027 (%)
- 6.4 DPP-4 inhibitor – Market size and forecast 2022-2027
- Exhibit 38: Chart on DPP-4 inhibitor – Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on DPP-4 inhibitor – Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on DPP-4 inhibitor – Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on DPP-4 inhibitor – Year-over-year growth 2022-2027 (%)
- 6.5 GLP-1 receptor agonists – Market size and forecast 2022-2027
- Exhibit 42: Chart on GLP-1 receptor agonists – Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on GLP-1 receptor agonists – Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on GLP-1 receptor agonists – Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on GLP-1 receptor agonists – Year-over-year growth 2022-2027 (%)
- 6.6 SGLT-2 inhibitors – Market size and forecast 2022-2027
- Exhibit 46: Chart on SGLT-2 inhibitors – Market size and forecast 2022-2027 ($ billion)
- Exhibit 47: Data Table on SGLT-2 inhibitors – Market size and forecast 2022-2027 ($ billion)
- Exhibit 48: Chart on SGLT-2 inhibitors – Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on SGLT-2 inhibitors – Year-over-year growth 2022-2027 (%)
- 6.7 Others – Market size and forecast 2022-2027
- Exhibit 50: Chart on Others – Market size and forecast 2022-2027 ($ billion)
- Exhibit 51: Data Table on Others – Market size and forecast 2022-2027 ($ billion)
- Exhibit 52: Chart on Others – Year-over-year growth 2022-2027 (%)
- Exhibit 53: Data Table on Others – Year-over-year growth 2022-2027 (%)
- 6.8 Market opportunity by Drug Class
- Exhibit 54: Market opportunity by Drug Class ($ billion)
7 Market Segmentation by Distribution Channel
- 7.1 Market segments
- Exhibit 55: Chart on Distribution Channel – Market share 2022-2027 (%)
- Exhibit 56: Data Table on Distribution Channel – Market share 2022-2027 (%)
- 7.2 Comparison by Distribution Channel
- Exhibit 57: Chart on Comparison by Distribution Channel
- Exhibit 58: Data Table on Comparison by Distribution Channel
- 7.3 Retail pharmacies – Market size and forecast 2022-2027
- Exhibit 59: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ billion)
- Exhibit 60: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ billion)
- Exhibit 61: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
- 7.4 Hospital pharmacies – Market size and forecast 2022-2027
- Exhibit 63: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ billion)
- Exhibit 64: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ billion)
- Exhibit 65: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
- 7.5 Online pharmacies – Market size and forecast 2022-2027
- Exhibit 67: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ billion)
- Exhibit 68: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ billion)
- Exhibit 69: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
- 7.6 Market opportunity by Distribution Channel
- Exhibit 71: Market opportunity by Distribution Channel ($ billion)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 73: Chart on Market share by geography 2022-2027 (%)
- Exhibit 74: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 75: Chart on Geographic comparison
- Exhibit 76: Data Table on Geographic comparison
- 9.3 North America – Market size and forecast 2022-2027
- Exhibit 77: Chart on North America – Market size and forecast 2022-2027 ($ billion)
- Exhibit 78: Data Table on North America – Market size and forecast 2022-2027 ($ billion)
- Exhibit 79: Chart on North America – Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on North America – Year-over-year growth 2022-2027 (%)
- 9.4 Europe – Market size and forecast 2022-2027
- Exhibit 81: Chart on Europe – Market size and forecast 2022-2027 ($ billion)
- Exhibit 82: Data Table on Europe – Market size and forecast 2022-2027 ($ billion)
- Exhibit 83: Chart on Europe – Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on Europe – Year-over-year growth 2022-2027 (%)
- 9.5 Asia – Market size and forecast 2022-2027
- Exhibit 85: Chart on Asia – Market size and forecast 2022-2027 ($ billion)
- Exhibit 86: Data Table on Asia – Market size and forecast 2022-2027 ($ billion)
- Exhibit 87: Chart on Asia – Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Asia – Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
- Exhibit 89: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
- Exhibit 90: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ billion)
- Exhibit 91: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
- 9.7 US – Market size and forecast 2022-2027
- Exhibit 93: Chart on US – Market size and forecast 2022-2027 ($ billion)
- Exhibit 94: Data Table on US – Market size and forecast 2022-2027 ($ billion)
- Exhibit 95: Chart on US – Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on US – Year-over-year growth 2022-2027 (%)
- 9.8 Germany – Market size and forecast 2022-2027
- Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ billion)
- Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ billion)
- Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
- 9.9 China – Market size and forecast 2022-2027
- Exhibit 101: Chart on China – Market size and forecast 2022-2027 ($ billion)
- Exhibit 102: Data Table on China – Market size and forecast 2022-2027 ($ billion)
- Exhibit 103: Chart on China – Year-over-year growth 2022-2027 (%)
- Exhibit 104: Data Table on China – Year-over-year growth 2022-2027 (%)
- 9.10 UK – Market size and forecast 2022-2027
- Exhibit 105: Chart on UK – Market size and forecast 2022-2027 ($ billion)
- Exhibit 106: Data Table on UK – Market size and forecast 2022-2027 ($ billion)
- Exhibit 107: Chart on UK – Year-over-year growth 2022-2027 (%)
- Exhibit 108: Data Table on UK – Year-over-year growth 2022-2027 (%)
- 9.11 India – Market size and forecast 2022-2027
- Exhibit 109: Chart on India – Market size and forecast 2022-2027 ($ billion)
- Exhibit 110: Data Table on India – Market size and forecast 2022-2027 ($ billion)
- Exhibit 111: Chart on India – Year-over-year growth 2022-2027 (%)
- Exhibit 112: Data Table on India – Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 113: Market opportunity by geography ($ billion)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 114: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 115: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 116: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 117: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 118: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 119: Matrix on vendor position and classification
- 12.3 Amgen Inc.
- Exhibit 120: Amgen Inc. – Overview
- Exhibit 121: Amgen Inc. – Product / Service
- Exhibit 122: Amgen Inc. – Key offerings
- 12.4 AstraZeneca Plc
- Exhibit 123: AstraZeneca Plc – Overview
- Exhibit 124: AstraZeneca Plc – Product / Service
- Exhibit 125: AstraZeneca Plc – Key news
- Exhibit 126: AstraZeneca Plc – Key offerings
- 12.5 Biocon Ltd.
- Exhibit 127: Biocon Ltd. – Overview
- Exhibit 128: Biocon Ltd. – Business segments
- Exhibit 129: Biocon Ltd. – Key offerings
- Exhibit 130: Biocon Ltd. – Segment focus
- 12.6 Boehringer Ingelheim International GmbH
- Exhibit 131: Boehringer Ingelheim International GmbH – Overview
- Exhibit 132: Boehringer Ingelheim International GmbH – Business segments
- Exhibit 133: Boehringer Ingelheim International GmbH – Key news
- Exhibit 134: Boehringer Ingelheim International GmbH – Key offerings
- Exhibit 135: Boehringer Ingelheim International GmbH – Segment focus
- 12.7 Cadila Pharmaceuticals Ltd.
- Exhibit 136: Cadila Pharmaceuticals Ltd. – Overview
- Exhibit 137: Cadila Pharmaceuticals Ltd. – Product / Service
- Exhibit 138: Cadila Pharmaceuticals Ltd. – Key offerings
- 12.8 Daiichi Sankyo Co. Ltd.
- Exhibit 139: Daiichi Sankyo Co. Ltd. – Overview
- Exhibit 140: Daiichi Sankyo Co. Ltd. – Business segments
- Exhibit 141: Daiichi Sankyo Co. Ltd. – Key news
- Exhibit 142: Daiichi Sankyo Co. Ltd. – Key offerings
- Exhibit 143: Daiichi Sankyo Co. Ltd. – Segment focus
- 12.9 Eli Lilly and Co.
- Exhibit 144: Eli Lilly and Co. – Overview
- Exhibit 145: Eli Lilly and Co. – Product / Service
- Exhibit 146: Eli Lilly and Co. – Key offerings
- 12.10 Glenmark Pharmaceuticals Ltd.
- Exhibit 147: Glenmark Pharmaceuticals Ltd. – Overview
- Exhibit 148: Glenmark Pharmaceuticals Ltd. – Product / Service
- Exhibit 149: Glenmark Pharmaceuticals Ltd. – Key offerings
- 12.11 Merck KGaA
- Exhibit 150: Merck KGaA – Overview
- Exhibit 151: Merck KGaA – Business segments
- Exhibit 152: Merck KGaA – Key news
- Exhibit 153: Merck KGaA – Key offerings
- Exhibit 154: Merck KGaA – Segment focus
- 12.12 Novartis AG
- Exhibit 155: Novartis AG – Overview
- Exhibit 156: Novartis AG – Business segments
- Exhibit 157: Novartis AG – Key offerings
- Exhibit 158: Novartis AG – Segment focus
- 12.13 Novo Nordisk AS
- Exhibit 159: Novo Nordisk AS – Overview
- Exhibit 160: Novo Nordisk AS – Business segments
- Exhibit 161: Novo Nordisk AS – Key offerings
- Exhibit 162: Novo Nordisk AS – Segment focus
- 12.14 Pfizer Inc.
- Exhibit 163: Pfizer Inc. – Overview
- Exhibit 164: Pfizer Inc. – Product / Service
- Exhibit 165: Pfizer Inc. – Key news
- Exhibit 166: Pfizer Inc. – Key offerings
- 12.15 Sanofi SA
- Exhibit 167: Sanofi SA – Overview
- Exhibit 168: Sanofi SA – Business segments
- Exhibit 169: Sanofi SA – Key news
- Exhibit 170: Sanofi SA – Key offerings
- Exhibit 171: Sanofi SA – Segment focus
- 12.16 Takeda Pharmaceutical Co. Ltd.
- Exhibit 172: Takeda Pharmaceutical Co. Ltd. – Overview
- Exhibit 173: Takeda Pharmaceutical Co. Ltd. – Product / Service
- Exhibit 174: Takeda Pharmaceutical Co. Ltd. – Key news
- Exhibit 175: Takeda Pharmaceutical Co. Ltd. – Key offerings
- 12.17 Tonghua Dongbao Pharmaceutical Co. Ltd.
- Exhibit 176: Tonghua Dongbao Pharmaceutical Co. Ltd. – Overview
- Exhibit 177: Tonghua Dongbao Pharmaceutical Co. Ltd. – Product / Service
- Exhibit 178: Tonghua Dongbao Pharmaceutical Co. Ltd. – Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 179: Inclusions checklist
- Exhibit 180: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 181: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 182: Research methodology
- Exhibit 183: Validation techniques employed for market sizing
- Exhibit 184: Information sources
- 13.5 List of abbreviations
- Exhibit 185: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio